recast-jats-buildd8e1462159jitcJ Immunother Cancer40425Journal for ImmunoTherapy of CancerJ Immunother Cancer2051-1426BMJ Publishing Group Ltds40425-018-0469-946910.1186/s40425-018-0469-930995944/jitc/7/1/107.atomCorrectionCorrection to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisJohnsonDaniel H.1ZobniwChrystia M.2TrinhVan A.2MaJunsheng3Bassett JrRoland L.3Abdel-WahabNoha45AndersonJaime2DavisJennifer E.6JosephJocelyn2UemuraMarc1NomanAli7Abu-SbeihHamzah7YeeCassian1AmariaRodabe1PatelSapna1TawbiHussein1GlitzaIsabella C.1DaviesMichael A.1WongMichael K.1WoodmanScott1HwuWen-Jen1HwuPatrick1WangYinghong7DiabAdi1x 0000 0001 2291 4776grid.240145.6Department of Melanoma Medical OncologyThe University of Texas MD Anderson Cancer Center Houston TX USA 0000 0001 2291 4776grid.240145.6Division of Pharmacy, Clinical SectionThe University of Texas MD Anderson Cancer Center Houston TX USA 0000 0001 2291 4776grid.240145.6Department of BiostatisticsThe University of Texas MD Anderson Cancer Center Houston TX USA 0000 0001 2291 4776grid.240145.6Section of Rheumatology and Clinical Immunology, Department of General Internal MedicineThe University of Texas MD Anderson Cancer Center Houston TX USA 0000 0004 0621 6144grid.411437.4Department of Rheumatology and Rehabilitation, Faculty of MedicineAssiut University Hospitals Assiut Egypt 0000 0001 2291 4776grid.240145.6Department of Epidemiology, Division of Cancer Prevention and Population SciencesThe University of Texas MD Anderson Cancer Center Houston TX USA 0000 0001 2291 4776grid.240145.6Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal MedicineThe University of Texas MD Anderson Cancer Center Houston TX USA adiab@mdanderson.org 122019174201918112019181120191742019711072711201829112018© The Author(s).2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Following publication of the original article [1], the authors reported an error in their listed affiliations.

publisher-imprint-nameBioMed Centralvolume-issue-count1issue-article-count0issue-toc-levels0issue-pricelist-year2019issue-copyright-holderThe Author(s)issue-copyright-year2019article-contains-esmNoarticle-numbering-styleUnnumberedarticle-registration-date-year2018article-registration-date-month11article-registration-date-day29article-toc-levels0toc-levels0volume-typeRegularjournal-productArchiveJournalnumbering-styleUnnumberedarticle-grants-typeOpenChoicemetadata-grantOpenAccessabstract-grantOpenAccessbodypdf-grantOpenAccessbodyhtml-grantOpenAccessbibliography-grantOpenAccessesm-grantOpenAccessonline-firstfalsepdf-file-referenceBodyRef/PDF/40425_2018_Article_469.pdfpdf-typeTypesettarget-typeOnlinePDFissue-typeRegulararticle-typeErratumjournal-subject-primaryMedicine & Public Healthjournal-subject-secondaryOncologyjournal-subject-secondaryImmunologyjournal-subject-collectionMedicine

Yinghong Wang and Adi Diab contributed equally to this work.

The original article can be found online at 10.1186/s40425-018-0412-0

Correction to: J Immunother Cancer

10.1186/s40425-018-0412-0

Following publication of the original article [1], the authors reported an error in their listed affiliations. This error was introduced during typesetting and the publisher apologizes to readers and the authors for the inconvenience.

In this Correction the authors are listed with their correct affiliations below.

Daniel H Johnson1, Chrystia M Zobniw2, Van A Trinh2, Junsheng Ma3, Roland L Bassett Jr3, Noha Abdel-Wahab4,5, Jaime Anderson2, Jennifer E Davis6, Jocelyn Joseph2, Marc Uemura1, Ali Noman7, Hamzah Abu-Sbeih7, Cassian Yee1, Rodabe Amaria1, Sapna Patel1, Hussein Tawbi1, Isabella C Glitza1, Michael A Davies1, Michael K Wong1, Scott Woodman1, Wen-Jen Hwu1, Patrick Hwu1, Yinghong Wang7 and Adi Diab1

1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2Division of Pharmacy, Clinical Section, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

5Department of Rheumatology and Rehabilitation, Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt

6Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

7Department of Gastroenterology, Hepatology, and Nutrition, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Reference Johnson DH , et al . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018;6:103 doi:10.1186/s40425-018-0412-0